Wednesday, January 19, 2022

Heron Therapeutics Inc. (HRTX) stock rose during pre-market. Let’s find out why?

Heron Therapeutics Inc. (NASDAQ: HRTX) stock surged by 11.38% at last close while the HRTX stock price gains by 7.53% in the pre-market trading session. Heron Therapeutics is an advertising biotechnology business dedicated to improving patients’ lives by discovering best-in-class therapies for some of the most serious unmet medical needs.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


HRTX stock’ Significant Update

The company reported that FDA has accepted a supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution, allowing the company to dramatically broaden the indication. ZYNRELEF is now approved for soft tissue or periarticular installation in adults to provide up to 72 hours of postsurgical analgesia.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


ZYNRELEF is the first-ever medication for surgical pain control that has been carefully examined in Phase 3 studies and shown to be better than the existing regular solution, bupivacaine solution. When contrasted to bupivacaine solution, ZYNRELEF provided greater, prolonged postoperative pain management for up to 72 hours and reduced the requirement for opioids, with more patients opioid-free. The FDA has validated that ZYNRELEF’s better efficacy exhibited in pivotal trials justifies its use in a larger spectrum of related surgical procedures with its approval.

ZYNRELEF’s increased indication will now cover about 7 million treatments each year. The use of ZYNRELEF in additional treatments allows doctors to minimize their patients’ requirement for opioids after surgery, which can have a good influence on the individuals and limit postoperative opioids that can contribute to overuse.

Moreover,

Postoperative opioids have been proved to be a gateway to addiction, with more than 2 million American citizens becoming chronic opioid users as a result of getting opioids after the operation. The largest number of fatal overdoses on record happened during the 12-month period ending April 2021, as per the Centers for Disease Control and Prevention, with over 100,000 Americans losing their lives.

Heron aims to file a new sNDA to the FDA in the second half of 2022 to establish a broad indication for soft tissue and orthopaedic surgical procedures, covering the complete 14 million target operations.

Latest news

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

CNFinance Holdings Ltd. (CNF) stock fell during after-hours, despite any current update.

CNFinance Holdings Ltd. (NASDAQ: CNF) stock declined by 20.27% in the after-hours trading session. CNFinance Holdings Limited is a significant provider of home equity...

Related news

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

CNFinance Holdings Ltd. (CNF) stock fell during after-hours, despite any current update.

CNFinance Holdings Ltd. (NASDAQ: CNF) stock declined by 20.27% in the after-hours trading session. CNFinance Holdings Limited is a significant provider of home equity...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam